$0.63
+0.03
(+4.22%)▲
5.7%
Downside
Day's Volatility :5.7%
Upside
0.0%
17.46%
Downside
52 Weeks Volatility :91.6%
Upside
89.82%
Period | Bionano Genomics Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -23.47% | 6.5% | 0.0% |
6 Months | -50.69% | 7.1% | 0.0% |
1 Year | -89.77% | 9.8% | 0.0% |
3 Years | -98.98% | 14.2% | -20.2% |
Market Capitalization | 51.2M |
Book Value | $1.44 |
Earnings Per Share (EPS) | -6.18 |
Wall Street Target Price | 6.33 |
Profit Margin | 0.0% |
Operating Margin TTM | -304.29% |
Return On Assets TTM | -35.84% |
Return On Equity TTM | -144.33% |
Revenue TTM | 37.5M |
Revenue Per Share TTM | 0.94 |
Quarterly Revenue Growth YOY | 18.3% |
Gross Profit TTM | 5.9M |
EBITDA | -115.5M |
Diluted Eps TTM | -6.18 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.74 |
EPS Estimate Next Year | -1.12 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 904.76%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 12.0M | ↑ 26.26% |
Net Income | -18.5M | ↓ 20.84% |
Net Profit Margin | -154.13% | ↑ 91.69% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 10.1M | ↓ 15.59% |
Net Income | -29.8M | ↑ 61.31% |
Net Profit Margin | -294.55% | ↓ 140.42% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 8.5M | ↓ 16.06% |
Net Income | -41.1M | ↑ 37.87% |
Net Profit Margin | -483.78% | ↓ 189.23% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 18.0M | ↑ 111.47% |
Net Income | -72.4M | ↑ 76.09% |
Net Profit Margin | -402.84% | ↑ 80.94% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 27.8M | ↑ 54.62% |
Net Income | -132.6M | ↑ 83.06% |
Net Profit Margin | -476.93% | ↓ 74.09% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 36.1M | ↑ 29.9% |
Net Income | -232.5M | ↑ 75.34% |
Net Profit Margin | -643.74% | ↓ 166.81% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 8.2M | ↑ 13.77% |
Net Income | -38.7M | ↑ 21.59% |
Net Profit Margin | -470.81% | ↓ 30.3% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 7.4M | ↓ 9.74% |
Net Income | -37.1M | ↓ 4.02% |
Net Profit Margin | -500.66% | ↓ 29.85% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 8.7M | ↑ 16.82% |
Net Income | -38.9M | ↑ 4.82% |
Net Profit Margin | -449.23% | ↑ 51.43% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 9.3M | ↑ 7.57% |
Net Income | -112.6M | ↑ 189.28% |
Net Profit Margin | -1.2K% | ↓ 758.82% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 10.7M | ↑ 15.06% |
Net Income | -43.9M | ↓ 61.01% |
Net Profit Margin | -409.39% | ↑ 798.66% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Revenue | 8.8M | ↓ 18.21% |
Net Income | -31.4M | ↓ 28.41% |
Net Profit Margin | -358.33% | ↑ 51.06% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 24.8M | ↑ 144.48% |
Total Liabilities | 14.7M | ↓ 75.71% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 30.2M | ↑ 21.79% |
Total Liabilities | 26.6M | ↑ 81.66% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 60.4M | ↑ 100.11% |
Total Liabilities | 25.4M | ↓ 4.78% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 377.1M | ↑ 523.83% |
Total Liabilities | 40.0M | ↑ 57.61% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 307.5M | ↓ 18.46% |
Total Liabilities | 58.1M | ↑ 45.33% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 214.4M | ↓ 30.28% |
Total Liabilities | 118.2M | ↑ 103.51% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 307.5M | ↓ 5.0% |
Total Liabilities | 58.1M | ↑ 38.49% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 292.2M | ↓ 4.99% |
Total Liabilities | 60.7M | ↑ 4.41% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 271.4M | ↓ 7.11% |
Total Liabilities | 56.6M | ↓ 6.66% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 181.9M | ↓ 32.97% |
Total Liabilities | 62.9M | ↑ 11.09% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 214.4M | ↑ 17.87% |
Total Liabilities | 118.2M | ↑ 87.98% |
Q1 FY24 | Q/Q Change | |
---|---|---|
Total Assets | 158.0M | ↓ 26.31% |
Total Liabilities | 75.2M | ↓ 36.38% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -19.9M | ↓ 4.2% |
Investing Cash Flow | -331.7K | ↓ 67.41% |
Financing Cash Flow | 35.8M | ↑ 103.18% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -29.5M | ↑ 48.06% |
Investing Cash Flow | -61.1K | ↓ 81.59% |
Financing Cash Flow | 30.4M | ↓ 15.09% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -38.3M | ↑ 29.75% |
Investing Cash Flow | -2.4M | ↑ 3912.63% |
Financing Cash Flow | 61.9M | ↑ 103.76% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -71.9M | ↑ 87.73% |
Investing Cash Flow | -278.1M | ↑ 11249.69% |
Financing Cash Flow | 336.1M | ↑ 442.98% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -124.8M | ↑ 73.53% |
Investing Cash Flow | 82.8M | ↓ 129.77% |
Financing Cash Flow | 23.0M | ↓ 93.15% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -34.5M | ↑ 17.11% |
Investing Cash Flow | 11.6M | ↑ 45.98% |
Financing Cash Flow | 146.0K | ↓ 99.36% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -32.4M | ↓ 6.1% |
Investing Cash Flow | 16.5M | ↑ 42.36% |
Financing Cash Flow | 14.9M | ↑ 10079.45% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -36.7M | ↑ 13.21% |
Investing Cash Flow | 29.6M | ↑ 78.94% |
Financing Cash Flow | 17.9M | ↑ 20.31% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -26.3M | ↓ 28.35% |
Investing Cash Flow | 33.4M | ↑ 13.02% |
Financing Cash Flow | 12.6M | ↓ 29.6% |
Sell
Neutral
Buy
Bionano Genomics Inc is currently in a neutral trading position according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Bionano Genomics Inc | -7.87% | -50.69% | -89.77% | -98.98% | -97.81% |
![]() Intuitive Surgical, Inc. | -1.32% | 16.54% | 32.6% | 35.62% | 148.32% |
![]() Resmed Inc. | 11.69% | 9.57% | -6.0% | -19.79% | 64.22% |
![]() Becton, Dickinson And Company | 0.5% | -1.64% | -17.69% | -6.68% | -8.49% |
![]() West Pharmaceutical Services Inc | -14.37% | -23.3% | -26.95% | -26.58% | 102.44% |
![]() Alcon Ag | 2.41% | 20.84% | 8.21% | 30.7% | 54.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Bionano Genomics Inc | NA | NA | NA | -1.74 | -1.44 | -0.36 | NA | 1.44 |
![]() Intuitive Surgical, Inc. | 78.14 | 78.14 | 7.13 | 6.63 | 0.16 | 0.08 | NA | 41.4 |
![]() Resmed Inc. | 32.24 | 32.24 | 1.75 | 7.73 | 0.22 | 0.12 | 0.01 | 31.52 |
![]() Becton, Dickinson And Company | 50.71 | 50.71 | 1.34 | 13.04 | 0.05 | 0.03 | 0.02 | 88.74 |
![]() West Pharmaceutical Services Inc | 42.71 | 42.71 | 6.72 | 7.74 | 0.21 | 0.11 | 0.0 | 36.72 |
![]() Alcon Ag | 44.05 | 44.05 | 4.59 | 3.07 | 0.05 | 0.02 | 0.0 | 42.13 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Bionano Genomics Inc | Buy | $51.2M | -97.81% | NA | 0.0% |
![]() Intuitive Surgical, Inc. | Buy | $161.3B | 148.32% | 78.14 | 27.65% |
![]() Resmed Inc. | Buy | $30.8B | 64.22% | 32.24 | 20.91% |
![]() Becton, Dickinson And Company | Buy | $68.6B | -8.49% | 50.71 | 6.76% |
![]() West Pharmaceutical Services Inc | Buy | $23.7B | 102.44% | 42.71 | 19.42% |
![]() Alcon Ag | Buy | $45.8B | 54.72% | 44.05 | 10.96% |
Insights on Bionano Genomics Inc
Revenue is down for the last 2 quarters, 10.72M → 8.76M (in $), with an average decrease of 18.2% per quarter
Netprofit is up for the last 3 quarters, -112.56M → -31.42M (in $), with an average increase of 98.1% per quarter
In the last 1 year, Intuitive Surgical, Inc. has given 32.6% return, outperforming this stock by 122.4%
In the last 3 years, Intuitive Surgical, Inc. has given 35.6% return, outperforming this stock by 134.6%
Vanguard Group Inc
GSA Capital Partners LLP
Geode Capital Management, LLC
BlackRock Inc
Cetera Investment Advisers
Cetera Advisors LLC
at bionano genomics®, we are committed to unlocking understanding of genome biology to advance the promise of genomics in areas including cancer and human disease, agricultural bioengineering and genome discovery. our team is not afraid to venture into uncharted territory to look for answers. we welcome the curious and provide a place where those who are not satisfied with the status quo can feel at home. our next-generation genome mapping and analysis tools help researchers see true genome structure to fill in what’s missing from sequencing-based data. saphyr™, our high-speed, high-throughput whole genome mapping solution, offers unmatched structural variation discovery capabilities and the ability to construct the most complete genome assemblies. at bionano, we are invested in the success of our customers and users around the world, and are dedicated to supporting them with the tools, resources and support they need to achieve their goals and make a real impact on improving quality o
Organization | Bionano Genomics Inc |
Employees | 344 |
CEO | Dr. Robert Erik Holmlin M.B.A., Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$0.63
+4.22%
Keyarch Acquisition Corp
$0.63
+4.22%
Connexa Sports Technologies Inc
$0.63
+4.22%
Us Value Etf
$0.63
+4.22%
First Wave Biopharma Inc
$0.63
+4.22%
Global X Msci Next Emerging
$0.63
+4.22%
Fat Projects Acquisition Corp
$0.63
+4.22%
Capital Link Global Fintech
$0.63
+4.22%
Applied Uv Inc
$0.63
+4.22%